Cyclerion shares jump 22.26% after-hours after announcing merger with Korsana and securing $380M in funding.

Cyclerion Therapeutics surged 22.26% in after-hours trading following the announcement of a definitive merger agreement with Korsana Biosciences, a privately-held biotechnology company. The all-stock transaction, expected to close in Q3 2026, provides Cyclerion shareholders with approximately 1.5% ownership in the combined company, which will operate under the Korsana name and trade as KRSA. The merger is supported by a $380 million private financing that will fund Korsana’s development through 2029, including key data readouts for its Alzheimer’s candidate, KRSA-028, in 2027. The deal is viewed as a strategic move to position Cyclerion in the high-growth neurodegenerative disease space and unlock long-term shareholder value.